(Adnkronos) - "Abbiamo numerose novità terapeutiche nel campo delle malattie infiammatorie croniche intestinali (Mici), cioè malattia di Crohn e colite ulcerosa. Si va sempre più verso la medicina personalizzata con un'ottica principale di mantenere la sostenibilità del sistema e cercare di garantire la sostenibilità con i costi che hanno queste terapie”. Lo ha detto Alessandro Armuzzi, Comitato Educazionale Ig-Ibd, intervenendo al XV Congresso Nazionale Ig-Ibd, il Gruppo italiano per lo studio delle malattie infiammatorie croniche intestinali, in corso a Riccione
Category
🗞
NewsTranscript
00:00Today we have many therapeutic innovations in the field of chronic intestinal inflammatory diseases such as Crohn's disease and colitis ulcerosa.
00:13Clearly, in addition to the importance of having new drugs available, the strategies we use are just as important.
00:21Today it has become clear that for Crohn's disease, it would be better to treat the patient immediately with advanced therapy in order to obtain the maximum result in that particular type of patient.
00:34Colitis ulcerosa is a little different because we still have to understand the timing of the treatment, but the recommendation is not to waste time and change therapy if the previous one is not working.
00:47Therefore, personalized medicine is increasingly used with the main aim of maintaining the sustainability of the system and guaranteeing sustainability with the costs of these therapies.